← Back to Screener
NeOnc Technologies Holdings, Inc. Common Stock (NTHI)
Price$4.54
Momentum ScoreF
Favorite Metrics
Price vs S&P 500 (26W)-37.68%
Price vs S&P 500 (4W)9.31%
VGM Score16.41
Market Capitalization$120.70M
All Metrics
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)25.98%
Cash Flow / Share (Quarterly)$-0.91
Price vs S&P 500 (YTD)-54.83%
EPS (TTM)$-3.20
10-Day Avg Trading Volume0.05M
EPS Excl Extra (TTM)$-3.20
EPS (Annual)$-3.20
Gross Margin (Annual)100.00%
Cash / Share (Quarterly)$0.08
ROA (Last FY)-348.19%
EBITD / Share (TTM)$-2.98
Cash Flow / Share (Annual)$-0.22
Net Income / Employee (Annual)$-12,429,200
Net Interest Coverage (TTM)-17.90x
ROA (TTM)-1032.75%
EPS Incl Extra (Annual)$-3.20
Current Ratio (Annual)0.25x
Quick Ratio (Quarterly)0.15x
3-Month Avg Trading Volume0.06M
52-Week Price Return-37.13%
Revenue / Employee (TTM)$8,000
P/S Ratio (Annual)3018.28x
Asset Turnover (Annual)0.02x
52-Week High$12.99
EPS Excl Extra (Annual)$-3.20
26-Week Price Return-21.75%
Quick Ratio (Annual)0.20x
13-Week Price Return-54.01%
Current Ratio (Quarterly)0.19x
Enterprise Value$123.89M
Revenue / Employee (Annual)$8,000
Pretax Margin (Annual)-155404.38%
Cash / Share (Annual)$0.00
3-Month Return Std Dev93.74%
Net Income / Employee (TTM)$-12,429,200
Net Interest Coverage (Annual)-16.62x
EPS Basic Excl Extra (Annual)$-3.20
EPS Incl Extra (TTM)$-3.20
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)-65.33%
Year-to-Date Return-43.89%
5-Day Price Return-13.11%
EPS Normalized (Annual)$-3.20
Net Profit Margin (Annual)-155404.38%
Month-to-Date Return4.98%
EBITD / Share (Annual)$-3.00
Operating Margin (Annual)-145637.53%
EPS Basic Excl Extra (TTM)$-3.20
Price vs S&P 500 (13W)-63.76%
Beta3.19x
Revenue / Share (TTM)$0.00
52-Week Low$3.20
mGradeF
vgmGradeF
Show chart for
Earnings Surprise History
Q1 26-0.35est. -0.22
Analyst Recommendations
May 2026
4.29
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
NTHINeOnc Technologies Holdings, Inc. Common Stock | — | — | F | $4.54 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
NeOnc Technologies develops molecular technology for targeted drug delivery to treat central nervous system diseases. The company's lead candidate, NEO100, is in Phase 2a clinical trials for glioblastoma and has received Orphan Drug and Fast Track designations from the FDA.